LU91062I2 - Adalimumab et ses dérivés pharmaceutiquement acceptables-trudexa - Google Patents

Adalimumab et ses dérivés pharmaceutiquement acceptables-trudexa

Info

Publication number
LU91062I2
LU91062I2 LU91062C LU91062C LU91062I2 LU 91062 I2 LU91062 I2 LU 91062I2 LU 91062 C LU91062 C LU 91062C LU 91062 C LU91062 C LU 91062C LU 91062 I2 LU91062 I2 LU 91062I2
Authority
LU
Luxembourg
Prior art keywords
htnfα
antibodies
human antibodies
recombinant human
antibody
Prior art date
Application number
LU91062C
Other languages
English (en)
Original Assignee
Abbott Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26707297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91062(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/599,226 external-priority patent/US6090382A/en
Application filed by Abbott Biotech Ltd filed Critical Abbott Biotech Ltd
Publication of LU91062I2 publication Critical patent/LU91062I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
LU91062C 1996-02-09 2004-02-25 Adalimumab et ses dérivés pharmaceutiquement acceptables-trudexa LU91062I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/599,226 US6090382A (en) 1996-02-09 1996-02-09 Human antibodies that bind human TNFα
US3147696P 1996-11-25 1996-11-25
PCT/US1997/002219 WO1997029131A1 (fr) 1996-02-09 1997-02-10 ANTICORPS HUMAINS SE FIXANT AU FACTEUR NECROSANT DES TUMEURS DE TYPE $g(a)

Publications (1)

Publication Number Publication Date
LU91062I2 true LU91062I2 (fr) 2004-04-26

Family

ID=26707297

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91062C LU91062I2 (fr) 1996-02-09 2004-02-25 Adalimumab et ses dérivés pharmaceutiquement acceptables-trudexa

Country Status (32)

Country Link
US (9) US6258562B1 (fr)
EP (1) EP0929578B1 (fr)
JP (8) JP3861118B2 (fr)
KR (1) KR100317188B1 (fr)
CN (5) CN101712720A (fr)
AT (1) ATE239041T1 (fr)
AU (1) AU722077B2 (fr)
BG (7) BG64776B1 (fr)
BR (3) BRPI9707379C8 (fr)
CA (1) CA2243459C (fr)
CY (2) CY2463B1 (fr)
CZ (1) CZ292465B6 (fr)
DE (4) DE69721548T2 (fr)
DK (1) DK0929578T3 (fr)
ES (1) ES2198552T3 (fr)
HK (4) HK1214607A1 (fr)
HU (4) HU221984B1 (fr)
IL (4) IL125697A (fr)
LU (1) LU91062I2 (fr)
MX (1) MX336813B (fr)
NL (1) NL300143I2 (fr)
NO (6) NO316711B1 (fr)
NZ (5) NZ562935A (fr)
PL (2) PL193499B1 (fr)
PT (1) PT929578E (fr)
RO (2) RO123028B1 (fr)
RU (3) RU2270030C2 (fr)
SI (1) SI9720020B (fr)
SK (1) SK284040B6 (fr)
TR (1) TR199801532T2 (fr)
UA (2) UA57726C2 (fr)
WO (1) WO1997029131A1 (fr)

Families Citing this family (477)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (fr) 1989-08-07 2001-03-07 Peptech Limited Ligands de liaison du facteur de necrose de tumeurs
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) * 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
CA2288994C (fr) 1997-04-30 2011-07-05 Enzon, Inc. Polypeptides a chaine unique modifies par oxyde de polyalkylene
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
WO2000036103A1 (fr) 1998-12-14 2000-06-22 Genetics Institute, Inc. Chaine de recepteurs de cytokine
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
CA2364026C (fr) * 1999-03-02 2012-08-21 Centocor, Inc. Anticorps anti-tnf.alpha. utilises dans la therapie de l'asthme
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2386457A1 (fr) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft Inhibiteurs de voie de signalisation de l'endotheline et antagonistes de recepteurs de l'integrine pour traitement combine
BR0108188A (pt) 2000-02-10 2003-02-25 Abbott Lab Anticorpos que se ligam a interleucina-18 humana e métodos de produção e uso
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP1355666B1 (fr) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation de "repulsive guidance molecule" (RGM) et de ses modulateurs
WO2002057423A2 (fr) * 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolement de cellules exprimant des protéines sécrétées
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
EP1379125A4 (fr) 2001-03-22 2004-12-08 Abbott Gmbh & Co Kg Animaux transgeniques exprimant des anticorps specifiques de genes donnes et utilisations de ceux-ci
US6410955B1 (en) * 2001-04-19 2002-06-25 Micron Technology, Inc. Comb-shaped capacitor for use in integrated circuits
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
PL222211B1 (pl) 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2002341766A1 (en) * 2001-09-20 2003-04-01 Genstar Therapeutics Corporation Improved methods for treatment with viral vectors
US20030065382A1 (en) * 2001-10-02 2003-04-03 Fischell Robert E. Means and method for the treatment of coronary artery obstructions
EP1432431B1 (fr) 2001-10-04 2017-05-10 Genetics Institute LLC Procedes et compositions permettant de moduler l'activite de l'interleukine-21
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
MY151032A (en) * 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004019861A2 (fr) * 2002-08-28 2004-03-11 Pharmacia Corporation Preparation optimisee a ph stable d'anticorps modifie
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20040162414A1 (en) * 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
US20040101939A1 (en) * 2002-11-22 2004-05-27 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
CA2508375C (fr) * 2002-12-02 2014-05-27 Abgenix, Inc. Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
MXPA05007019A (es) * 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004063335A2 (fr) * 2003-01-08 2004-07-29 Applied Molecular Evolution Molecules de liaison au facteur de necrose tumorale alpha
JP2006517789A (ja) * 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0408315A (pt) 2003-03-14 2006-03-07 Wyeth Corp anticorpo isolado, composição farmacêutica, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos de produzir um anticorpo, de gerar um anticorpo ou fragmento de ligação de antìgeno, de regular uma resposta imune, de tratar ou prevenir um distúrbio associado com célula imune em um paciente, de tratar ou prevenir um distúrbio hiperproliferativo em um paciente, e, kit de diagnóstico
EP1460088A1 (fr) 2003-03-21 2004-09-22 Biotest AG Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives
WO2004098578A2 (fr) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprenant un inhibiteur de la pde4 et un antagoniste du tnf?
FR2856075B1 (fr) * 2003-06-16 2007-10-12 Monoclonal Antibodies Therapeu Procede essentiellement automatise de criblage a grande echelle de cellules secretant des anticorps monoclonaux
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
MXPA06010673A (es) 2004-03-19 2007-06-20 Amgen Inc Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
US7625549B2 (en) * 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
MX2007001509A (es) * 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
WO2006041970A2 (fr) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Infection a virus respiratoire syncytial (rsv)
WO2007001420A2 (fr) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolement d'anticorps humains
EP1827491A4 (fr) 2004-11-19 2010-07-14 Biogen Idec Inc Traitement de la sclerose en plaques
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
JP2008532493A (ja) * 2005-02-14 2008-08-21 ワイス Ｉｌ−１７ｆとｉｌ−１７ｒとの間の相互作用の特性解析
TW200641353A (en) * 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
EP1859277A4 (fr) 2005-02-17 2010-03-17 Biogen Idec Inc Traitement de troubles neurologiques
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
AU2012254978C1 (en) * 2005-05-16 2017-06-01 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
US20070020660A1 (en) * 2005-06-06 2007-01-25 Burczynski Michael E Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US20060286108A1 (en) * 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds
WO2006138690A2 (fr) * 2005-06-17 2006-12-28 Abbott Laboratories Methode amelioree de traitement d'affections vertebrales degeneratives
KR101446503B1 (ko) * 2005-06-24 2014-10-06 듀크 유니버시티 열 반응성 생중합체에 기초한 직접 약물 전달 시스템
KR20080031024A (ko) 2005-07-21 2008-04-07 아보트 러보러터리즈 폴리단백질, 프로단백질 및 단백질분해를 사용한 ｓＯＲＦ작제물 포함 다중 유전자 발현 및 방법
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
EP2500357A3 (fr) 2005-08-19 2012-10-24 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
AU2006283532B2 (en) 2005-08-19 2012-04-26 Abbvie Inc. Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
CA2624562A1 (fr) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
WO2007049286A1 (fr) * 2005-10-27 2007-05-03 Tata Memorial Centre Systeme de separation ex vivo de particules de chromatine apoptotiques du sang ou du plasma
NZ567286A (en) 2005-11-01 2012-03-30 Abbott Biotechnolgy Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
CA2628703C (fr) 2005-11-30 2019-10-29 Abbott Laboratories Anticorps anti-globulomere a.beta., fractions de liaison aux antigenes de ceux-ci, hydridomes , acides nucleiques, vecteurs, cellules hotes correspondants, procedes de production des anticorps, compositions comprenant les anticorps, utilisations des anticorps et procedes d'utilisation de ces anticorps
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
WO2007087673A1 (fr) 2006-02-01 2007-08-09 Arana Therapeutics Limited Produit d'assemblage d'anticorps à domaines
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
WO2007120626A2 (fr) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
WO2007120656A2 (fr) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (fr) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite psoriasique
EP2666478A3 (fr) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Utilisations et compositions pour le traitement du psoriasis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
JP5535623B2 (ja) 2006-06-30 2014-07-02 アッヴィ バイオテクノロジー リミテッド 自動注射装置
KR101625961B1 (ko) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP2500416A1 (fr) 2006-09-13 2012-09-19 Abbott Laboratories Améliorations de culture cellulaire
EP2684895A1 (fr) * 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Anticorps anti-hTNfalpha cristallins
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
US20080206241A1 (en) 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8324350B2 (en) 2006-12-29 2012-12-04 Abbott Laboratories Dual-specific IL-1α/IL-1β antibodies
CA2675233A1 (fr) * 2007-01-16 2008-07-24 Abbott Laboratories Procedes de traitement d'un psoriasis
JP2008209378A (ja) * 2007-01-31 2008-09-11 Fujifilm Corp バイオセンサー基板
DK2148691T3 (en) 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
US8280711B2 (en) * 2007-03-12 2012-10-02 ESBATech, an Alcon Biomedical Research Unit, LLC. Sequence based engineering and optimization of single chain antibodies
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
WO2008124858A2 (fr) * 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Récepteur ciblé
EP2165194A4 (fr) 2007-05-31 2010-09-08 Abbott Lab BIOMARQUEURS PRÉDICTIFS DE LA RÉACTIVITÉ AUX INHIBITEURS TNF-alpha DANS DES TROUBLES AUTO-IMMUNS
WO2008150490A2 (fr) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Compositions et utilisations pour le traitement du psoriasis et de la maladie de crohn
CA2683791A1 (fr) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
AU2008259513B2 (en) * 2007-06-06 2014-07-24 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
LT2170390T (lt) 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
WO2009000099A2 (fr) * 2007-06-25 2008-12-31 Esbatech Ag Méthodes de modification d'anticorps et anticorps modifiés présentant des propriétés fonctionnelles améliorées
DK2164961T3 (en) * 2007-06-25 2015-03-02 Esbatech Alcon Biomed Res Unit Sequence based forward position and optimization of single chain ​​antibodies
CA2693771A1 (fr) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Compositions et methodes d'administration pulmonaire d'un inhibiteur du tnf.alpha.
WO2009020654A1 (fr) 2007-08-08 2009-02-12 Abbott Laboratories Compositions et procédés permettant la cristallisation d'anticorps
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
WO2009032128A1 (fr) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions et procédés comprenant des protéines de liaison pour adalimumab
JP2009082033A (ja) * 2007-09-28 2009-04-23 Kaneka Corp 完全ヒト型抗体生産法
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
WO2009062151A1 (fr) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions et procédés de production d'anticorps
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
CA2710333A1 (fr) * 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Prediction de l'efficacite a long terme d'un compose dans le traitement du psoriasis
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
ES2569217T3 (es) 2008-03-13 2016-05-09 Biotest Ag Agente para tratar enfermedades
ES2610327T3 (es) 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
US8557239B2 (en) * 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
EP2899209A1 (fr) 2008-04-29 2015-07-29 Abbvie Inc. Immunoglobuline à double domaine variable et ses utilisations
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2113568A1 (fr) 2008-04-30 2009-11-04 Deutsches Rheuma-Forschungszentrum Berlin Souris " knock-in" comme modèle pour le criblage les bloquants du TNF-alpha humain
CA2723219A1 (fr) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Anticorps contre le recepteur des produits terminaux de glycation avancee (rage) et leurs utilisations
WO2009142186A1 (fr) * 2008-05-20 2009-11-26 株式会社カネカ Composition cytotoxique
BRPI0913406A2 (pt) 2008-06-03 2018-01-09 Abbott Lab imunoglobulinas de domínio variável duplo e usos das mesmas
EP2297208A4 (fr) 2008-06-03 2012-07-11 Abbott Lab Immunoglobulines à double domaine variable et leurs utilisations
CN110372792A (zh) 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
PT3241843T (pt) 2008-06-25 2021-09-10 Novartis Ag Otimização da solubilidade de imunoligantes
LT3444274T (lt) 2008-06-25 2021-03-25 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys tnf
WO2009158704A2 (fr) 2008-06-27 2009-12-30 Duke University Agents thérapeutiques comprenant des peptides de type élastine
US20110177070A1 (en) * 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
BRPI0915825A2 (pt) 2008-07-08 2015-11-03 Abbott Lab proteínas de ligação à prostaglandina e2 usos das mesmas
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US20110159011A1 (en) * 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
CN102281898B (zh) * 2008-10-07 2015-06-03 成功大学 Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
WO2010056550A1 (fr) 2008-10-29 2010-05-20 Wyeth Llc Procédés de purification de molécules de liaison d’antigène monodomaines
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
CN101419224B (zh) * 2008-11-06 2012-08-22 复旦大学附属华山医院 一种同时测定人血浆中霉酚酸酯、霉酚酸及其代谢物的方法
EP2350649A4 (fr) * 2008-11-28 2012-11-14 Abbott Lab Compositions d'anticorps stables et procédés pour stabiliser celles-ci
CN101766602B (zh) * 2008-12-30 2012-01-11 中国医学科学院血液病医院（血液学研究所） 取代芳香基腙类化合物在作为肿瘤坏死因子抑制剂药物方面的应用
KR20110110247A (ko) 2008-12-30 2011-10-06 센토코 오르토 바이오테크 인코포레이티드 강직성 척추염 환자에서 항-ＴＮＦα 항체에 대한 임상적 반응을 예측하는 혈청 마커
EP3543256A1 (fr) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Compositions d anticorps modifiées et leurs procédés de production et d'utilisation
EP2398494A4 (fr) 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proprotéines et leurs procédés d'utilisation
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
TW201613969A (en) * 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
CN101875694B (zh) * 2009-04-28 2014-04-02 中国医学科学院基础医学研究所 TNFα的抗体及其用途
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
WO2010129469A1 (fr) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Formulations stables à concentration protéique élevée d'anticorps anti-tnf-alpha humain
WO2010132872A1 (fr) * 2009-05-15 2010-11-18 Novimmune S.A Polythérapies et méthodes utilisant des agents de modulation anti-cd3 et des antagonistes anti-tnf
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
HUE054744T2 (hu) 2009-08-14 2021-12-28 Phasebio Pharmaceuticals Inc Módosított vazoaktív intesztinális peptidek
AU2010283997B2 (en) * 2009-08-21 2015-04-09 Gilead Biologics, Inc. Methods and compositions for treatment of pulmonary fibrotic disorders
CA2771575A1 (fr) 2009-08-29 2011-03-03 Abbott Laboratories Proteines therapeutiques se liant a dll4
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
CA2775291A1 (fr) * 2009-09-24 2011-03-31 Xbiotech, Inc. Procedes, compositions et necessaires pour reduire les reponses aux anti-anticorps
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2796530T3 (es) * 2009-10-26 2020-11-27 Prometheus Biosciences Inc Ensayos para la detección de fármacos anti-TNF y autoanticuerpos
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053699A1 (fr) * 2009-10-30 2011-05-05 Abbott Laboratories Produits de recombinaison à sorf et expression de multiple gène
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US9244063B2 (en) 2009-11-11 2016-01-26 Gentian As Immunoassay for assessing related analytes of different origin
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011068927A2 (fr) * 2009-12-04 2011-06-09 Abbott Laboratories Inhibiteurs de la 11-β-hydroxystéroïde déshydrogénase de type 1 (11b-hsd1) et leurs utilisations
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
NZ600069A (en) 2009-12-15 2015-02-27 Abbvie Biotechnology Ltd Improved firing button for automatic injection device
JP2013514388A (ja) 2009-12-16 2013-04-25 フィリップ ボッシュ， 間質性膀胱炎の処置の方法
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
WO2011092715A2 (fr) * 2010-01-27 2011-08-04 Tata Memorial Centre Procédé pour la liaison in vivo de fragments de chromatine
US20120014956A1 (en) 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
CN102167741B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
CA2791631A1 (fr) 2010-03-02 2011-09-09 Abbvie Inc. Proteines therapeutiques de liaison a dll4
EP3372617B1 (fr) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
ES2805873T3 (es) 2010-04-16 2021-02-15 Biogen Ma Inc Anticuerpos anti-VLA-4
SG10201503130UA (en) 2010-04-21 2015-06-29 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
RS57543B1 (sr) 2010-06-03 2018-10-31 Abbvie Biotechnology Ltd Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
WO2012006500A2 (fr) 2010-07-08 2012-01-12 Abbott Laboratories Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012009705A1 (fr) 2010-07-15 2012-01-19 Zyngenia, Inc. Complexes liant ang-2 et leurs utilisations
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012024187A1 (fr) 2010-08-14 2012-02-23 Abbott Laboratories Protéines de liaison bêta-amyloïdes
EP3333188B1 (fr) 2010-08-19 2022-02-09 Zoetis Belgium S.A. Anticorps anti-ngf et leur utilisation
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2632436B1 (fr) 2010-10-29 2018-08-29 Abbvie Inc. Dispersions solides contenant un agent induisant l'apoptose
JP2014500712A (ja) * 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗ｔｎｆアルファ抗体液体製剤
WO2012071336A1 (fr) 2010-11-23 2012-05-31 Abbott Laboratories Sels et formes cristallines d'un agent inducteur d'apoptose
PT2642999T (pt) 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Métodos de tratamento que utilizam inibidores seletivos de bcl-2
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
KR20130133247A (ko) 2010-12-21 2013-12-06 애브비 인코포레이티드 Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
EP2490024A1 (fr) 2010-12-22 2012-08-22 Proteomika, S.L. Procédé pour optimiser le traitement de patients au moyen de médicaments biologiques
CN106075664B (zh) 2011-01-24 2019-07-02 艾伯维生物技术有限公司 具有模制抓握面的自动注射装置
AU2012210170B2 (en) 2011-01-24 2016-09-29 Elcam Medical Agricultural Cooperative Association Ltd. Injector
MX342163B (es) 2011-01-24 2016-09-19 Abbvie Biotechnology Ltd Separacion de protectores de aguja de jeringas y dispositivos de inyeccion automaticos.
RU2455025C1 (ru) * 2011-02-10 2012-07-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ фармакологической коррекции ишемии конечности смесью растворов гомеопатических разведений
WO2012121403A1 (fr) 2011-03-07 2012-09-13 The University Of Tokushima Procédé de traitement de la sclérose latérale amyotrophique
JP2014511711A (ja) 2011-03-18 2014-05-19 アッヴィ・インコーポレイテッド 自動注入デバイスおよびそのサブアセンブリを組み立てるためのシステム、デバイス、および方法
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2669198T5 (es) 2011-03-29 2021-07-20 Abbvie Inc Despliegue de envolvente mejorado en dispositivos de inyección automáticos
WO2012145752A2 (fr) 2011-04-21 2012-10-26 Abbott Laboratories Dispositif d'injection automatique portable pour administration contrôlée d'agents thérapeutiques
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
DK2715352T3 (da) 2011-05-31 2019-05-20 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
EP2717902B1 (fr) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Utilisation de peptides intestinaux vasoactifs (piv) modifiés pour traiter l'hypertension
CN103857411A (zh) 2011-07-13 2014-06-11 阿布维公司 使用抗il-13抗体治疗哮喘的方法和组合物
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CA2843315A1 (fr) * 2011-08-01 2013-02-07 Avaxia Biologics, Inc. Anticorps polyclonal bovin specifique du tnf humain
CN109608543A (zh) * 2011-10-20 2019-04-12 艾斯巴技术-诺华有限责任公司 稳定的多抗原结合抗体
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
HK1200321A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Bispecific immunobinders directed against tnf and il-17
IN2014CN03936A (fr) 2011-10-24 2015-09-04 Abbvie Inc
WO2013080050A2 (fr) 2011-11-30 2013-06-06 Universitaetsklinikum Erlangen Procédés et compositions pour déterminer la réactivité à des traitements avec un inhibiteur de tnf-alpha
JP6342812B2 (ja) 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
EP2791175A2 (fr) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition et méthode pour le diagnostic et le traitement de troubles liés au fer
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
TW201333033A (zh) 2011-12-30 2013-08-16 Abbvie Inc 雙可變域免疫球蛋白及其用途
EP2807192B1 (fr) 2012-01-27 2018-04-18 Abbvie Deutschland GmbH & Co. KG Composition et méthode pour le diagnostic et le traitement de maladies associées à la dégénérescence des neurites
MX363700B (es) 2012-03-07 2019-03-29 Cadila Healthcare Ltd Formulaciones farmaceuticas de anticuerpos tnf-alfa.
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
EP2657334B1 (fr) 2012-04-26 2016-07-06 GeneFrontier Corporation Procédé efficace pour afficher un multimère de protéine
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2894852T3 (es) 2012-06-06 2022-02-16 Zoetis Services Llc Anticuerpos anti-NGF caninizados y métodos de los mismos
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201501715QA (en) 2012-09-07 2015-05-28 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
AU2013318147B2 (en) * 2012-09-19 2018-01-04 Abbvie Biotherapeutics Inc. Methods for identifying antibodies with reduced immunogenicity
SG11201503324WA (en) 2012-11-01 2015-05-28 Abbvie Inc Stable dual variable domain immunoglobulin protein formulations
UY35110A (es) 2012-11-01 2014-05-30 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
TWI745610B (zh) 2012-11-14 2021-11-11 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
WO2014106001A2 (fr) 2012-12-28 2014-07-03 Abbvie, Inc. Protéines de liaison doublement spécifiques ayant une séquence récepteur
WO2014123696A1 (fr) 2013-01-25 2014-08-14 Thymon, Llc Compositions pour la réduction sélective de tnf soluble bioactif en circulation et méthodes de traitement d'une maladie à médiation par tnf
JP2016508515A (ja) 2013-02-13 2016-03-22 ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用
EP2830651A4 (fr) 2013-03-12 2015-09-02 Abbvie Inc Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
SG11201507365VA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing the same using displacement chromatography
CA2926384A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Compositions d'especes faiblement acides et leurs procedes de production et d'utilisation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (fr) * 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014143342A1 (fr) 2013-03-14 2014-09-18 Abbott Laboratories Antigènes recombinants ns3 de vhc et leurs mutants pour la détection d'anticorps améliorée
WO2014143343A1 (fr) 2013-03-14 2014-09-18 Abbott Laboratories Anticorps monoclonaux à domaine de liaison à un lipide du cœur de vhc
TW201446800A (zh) 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CA2904448A1 (fr) 2013-03-15 2014-09-18 Tariq Ghayur Proteines de liaison specifiques a domaines variables doubles dirigees contre il-1.beta. et/ou il-17
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
AU2014269287B2 (en) * 2013-05-22 2016-08-25 Seoul National University Hospital Anti-TNF-alpha/CXCL10 double-targeting antibody and use thereof
CA2914566A1 (fr) 2013-06-07 2014-12-11 Duke University Inhibiteurs du facteur h du complement
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015017683A1 (fr) * 2013-07-31 2015-02-05 Malast Mary Compositions antimicrobiennes et méthodes d'utilisation associées
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
CA2926644A1 (fr) 2013-10-06 2015-04-09 Abbvie Inc. Proteines de liaison specifiques doubles dirigees contre des recepteurs de cellules immunitaires et des auto-antigenes
WO2015054658A1 (fr) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
WO2015057910A1 (fr) 2013-10-16 2015-04-23 Oncobiologics, Inc. Formulations de tampon pour stabilité d'anticorps améliorée
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2931978A1 (fr) 2013-12-02 2015-06-11 Abbvie Inc. Compositions et methodes pour traiter l'arthrose
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
US10955422B2 (en) 2014-02-27 2021-03-23 Biogen Ma, Inc. Method of assessing risk of PML
EP3674310A1 (fr) 2014-03-10 2020-07-01 Richter Gedeon Nyrt. Purification d'immunoglobuline à l'aide d'étapes de prénettoyage
JP2017511376A (ja) 2014-03-21 2017-04-20 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート
AR099625A1 (es) * 2014-03-21 2016-08-03 Lilly Co Eli Anticuerpos de il-21
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
ES2818824T3 (es) 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
LT2946765T (lt) 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
EP2946767B1 (fr) 2014-05-23 2016-10-05 Ares Trading S.A. Composition pharmaceutique liquide
EP2946766B1 (fr) 2014-05-23 2016-03-02 Ares Trading S.A. Composition pharmaceutique liquide
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha
EP3145951A1 (fr) 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
AU2015283270B9 (en) * 2014-06-30 2021-04-01 Merck Patent Gmbh Anti-TNFa antibodies with pH-dependent antigen binding
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
US10755801B2 (en) 2014-07-11 2020-08-25 Iogenetics, Llc Identifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database
UA123624C2 (uk) * 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
US10435464B1 (en) 2014-09-05 2019-10-08 Coherus Biosciences, Inc. Methods for making recombinant proteins
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
WO2016103093A1 (fr) 2014-12-23 2016-06-30 Pfizer Inc. Formulation d'anticorps aqueuse stable pour des anticorps anti tnf alpha
EP3085709B1 (fr) 2014-12-28 2019-08-21 Genor Biopharma Co., Ltd Anticorps anti-rankl humain humanisé, composition pharmaceutique et son utilisation
EP3247718B1 (fr) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation de variants de charge dans une composition d'anticorps monoclonaux
EP3053572A1 (fr) 2015-02-06 2016-08-10 Ares Trading S.A. Composition pharmaceutique liquide
CN114652817A (zh) 2015-02-09 2022-06-24 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
CN105777905B (zh) * 2015-03-24 2019-06-25 广东东阳光药业有限公司 一种全人源抗TNF-α单克隆抗体及其应用
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
WO2016179469A1 (fr) * 2015-05-07 2016-11-10 Abbvie Inc. Méthodes et compositions de diagnostic et de traitement de la maladie intestinale inflammatoire
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
HU231463B1 (hu) 2015-08-04 2024-01-28 Richter Gedeon Nyrt. Módszer rekombináns proteinek galaktóz tartalmának növelésére
US11583584B1 (en) 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2017136433A1 (fr) 2016-02-03 2017-08-10 Oncobiologics, Inc. Formulations de tampon pour améliorer la stabilité d'anticorps
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
WO2017158101A1 (fr) * 2016-03-17 2017-09-21 Numab Innovation Ag Anticorps anti-tnfα et fragments fonctionnels de ceux-ci
LT3219726T (lt) * 2016-03-17 2021-01-25 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
EP3440113A1 (fr) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
LT3464318T (lt) 2016-06-02 2021-06-25 Abbvie Inc. Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3468615A1 (fr) 2016-06-08 2019-04-17 AbbVie Inc. Conjugué médicament-anticorps anti-egfr
CA3027181A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Conjugues medicament-anticorps anti-egfr
UY37278A (es) 2016-06-08 2018-01-31 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
EP3472197A1 (fr) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Anticorps à domaines ch2 modifiés, compositions les contenant et leurs procédés d'utilisation
WO2018018613A1 (fr) 2016-07-29 2018-02-01 广东东阳光药业有限公司 Milieu de culture et procédé de culture cellulaires pour augmenter la pureté d'un anticorps
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
LT3506921T (lt) 2016-08-31 2023-08-10 Mapi Pharma Ltd Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
WO2018045258A1 (fr) * 2016-09-02 2018-03-08 The University Of Chicago Traitement de cytotoxicité du tnf-alpha
US11453726B2 (en) * 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
CN110383068A (zh) 2016-10-03 2019-10-25 雅培实验室 评估患者样品中uch-l1状态的改进方法
WO2018075408A1 (fr) 2016-10-17 2018-04-26 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la leucémie myéloïde aiguë (lam) avec des combinaisons d'anticorps anti-cd200, de cytarabine et de daunorubicine
WO2018075818A1 (fr) 2016-10-21 2018-04-26 Amgen Inc. Formulations pharmaceutiques et leurs procédés de préparation
WO2018102594A1 (fr) 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Procédés de traitement de tumeurs solides avec des anticorps anti-cd200
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
JP7150724B2 (ja) 2016-12-14 2022-10-11 ビオラ・セラピューティクス・インコーポレイテッド 消化管疾病のｔｎｆ阻害薬による治療
CN110234348B (zh) 2016-12-16 2024-06-25 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
EP3558363A1 (fr) 2016-12-21 2019-10-30 Amgen Inc. Formulations d'anticorps anti-tnf alpha
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
CA3049857A1 (fr) * 2017-01-11 2018-07-19 Celltrion Inc. Formulation liquide stable
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
CA3052095A1 (fr) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anticorps anti-tnf, compositions et methodes pour le traitement du rhumatisme psoriasique actif
IL319561A (en) 2017-02-07 2025-05-01 Janssen Biotech Inc Anti-TNF antibodies, compositions and methods for treating active ankylosing spondylitis
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
EP3372242A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
CA3052513A1 (fr) 2017-03-23 2018-09-27 Abbott Laboratories Methodes d'aide au diagnostic et a la determination de l'etendue d'une lesion cerebrale traumatique chez un sujet humain a l'aide du biomarqueur precoce hydrolase carboxy-terminale d'ubiquitine l1
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2018184692A1 (fr) 2017-04-07 2018-10-11 Ares Trading S.A. Composition pharmaceutique liquide
US10877048B2 (en) 2017-04-15 2020-12-29 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
CN110651190A (zh) 2017-05-25 2020-01-03 雅培实验室 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
WO2018222783A1 (fr) 2017-05-30 2018-12-06 Abbott Laboratories Procédés d'aide au diagnostic et à l'évaluation d'une lésion cérébrale traumatique légère chez un sujet humain au moyen de troponine i cardiaque et de biomarqueurs précoces
CA3068041C (fr) 2017-07-03 2024-06-25 Abbott Laboratories Procedes ameliores de mesure de niveaux d'hydrolase a terminaison carboxy d'ubiquitine l1 dans le sang
WO2019067499A1 (fr) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Signature de biomarqueur pour la prédiction d'une réponse tumorale vis-à-vis d'une thérapie anti-cd200
PE20201286A1 (es) 2017-12-01 2020-11-24 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados de este
CN109879962B (zh) * 2017-12-06 2022-10-11 北京科立思维生物科技有限公司 抗tnf单链抗体、抗il-6单链抗体及其融合蛋白及其应用
CN111094983A (zh) 2017-12-09 2020-05-01 雅培实验室 使用胶质细胞原纤维酸性蛋白(gfap)和/或泛素羧基末端水解酶l1(uch-l1)帮助诊断和评价已遭受骨科损伤并已遭受或可能已遭受头部损伤诸如轻度创伤性脑损伤(tbi)的患者的方法
JP7379165B2 (ja) 2017-12-09 2023-11-14 アボット・ラボラトリーズ Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
WO2019126133A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Formulations liquides d'anticorps anti-cd200
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
JP7331000B2 (ja) 2018-03-26 2023-08-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ３転換酵素のプロテアーゼ活性を測定するためのスループットの高い方法
CN112867394B9 (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CA3103664A1 (fr) 2018-07-03 2020-01-09 Novartis Ag Methodes de traitement ou de selection d'un traitement pour un sujet resistant a un inhibiteur de tnf a l'aide d'un antagoniste de nlrp3
CN113329769A (zh) 2018-10-11 2021-08-31 斯克里普斯研究学院 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物
EP3870168A1 (fr) 2018-10-24 2021-09-01 Novartis AG Composés et compositions pour traiter des états associés à l'activité d'un nlrp
AU2019374190B2 (en) 2018-11-05 2024-02-22 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
WO2020102098A1 (fr) 2018-11-13 2020-05-22 Novartis Inflammasome Research, Inc. Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp
WO2020102100A1 (fr) 2018-11-13 2020-05-22 Novartis Inflammasome Research, Inc. Composés et compositions destinés au traitement d'états pathologiques associés à une activité nlrp
WO2020106757A1 (fr) 2018-11-19 2020-05-28 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique au tube digestif
WO2020118011A1 (fr) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anticorps anti-alk2 et leurs utilisations
ES3031988T3 (en) 2018-12-25 2025-07-14 Beijing Baishihekang Pharmaceutical Tech Bsjpharma Co Ltd Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
WO2020154321A1 (fr) 2019-01-22 2020-07-30 Novartis Inflammasome Research, Inc. Composés et compositions pour traiter des états associés à une activité de nlrp
HU231498B1 (hu) 2019-04-04 2024-05-28 Richter Gedeon Nyrt Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
WO2021002887A1 (fr) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
EP3997124A4 (fr) * 2019-07-09 2024-01-03 National Institute for Biotechnology in the Negev Ltd. Anticorps présentant une immunogénicité réduite
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
FR3104582A1 (fr) 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Tat peptide binding proteins and uses thereof
WO2021178597A1 (fr) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
EP4136459A1 (fr) 2020-04-13 2023-02-22 Abbott Laboratories Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
EP4149548A4 (fr) 2020-05-13 2024-05-08 Disc Medicine, Inc. Anticorps anti-hémojuvéline (hjv) pour le traitement de la myélofibrose
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
KR20230042301A (ko) 2020-08-04 2023-03-28 애벗트 라보라토리이즈 샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
CN111944052B (zh) * 2020-08-26 2022-02-11 中国药科大学 抗TNF-α/PD-1双特异性抗体及其应用
CN112010970B (zh) * 2020-10-30 2021-01-12 迈威(上海)生物科技股份有限公司 一种去除重组表达抗体聚体和降解产物的方法
CA3198161A1 (fr) 2020-12-01 2022-06-09 Beth MCQUISTON Utilisation d'un ou plusieurs biomarqueurs pour determiner un traumatisme cranien (tbi) chez un sujet soumis a un balayage de tomodensitometrie assistee par ordinateur de la tete a tbi negati
WO2023102384A1 (fr) 2021-11-30 2023-06-08 Abbott Laboratories Utilisation d'un ou de plusieurs biomarqueurs pour déterminer un traumatisme crânien (tbi) chez un sujet ayant été soumis à un balayage de tomodensitométrie assistée par ordinateur de la tête ne démontrant par de tbi
US11672929B2 (en) 2020-12-02 2023-06-13 Breathe Restore, Inc. Product delivery devices and methods
US20240270859A1 (en) 2020-12-09 2024-08-15 Hk Inno.N Corporation ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFa BISPECIFIC ANTIBODY, AND USES THEREOF
CA3202331A1 (fr) * 2020-12-18 2022-06-23 Stephanie A. Pierce Anticorps anti-tnf? et ngf a usage veterinaire
EP4271998A1 (fr) 2020-12-30 2023-11-08 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4294827A1 (fr) 2021-02-19 2023-12-27 Theripion, Inc. Polypeptides de fusion paraoxonase et compositions et méthodes associées
WO2022232286A1 (fr) 2021-04-27 2022-11-03 Generation Bio Co. Vecteurs d'adn non viraux exprimant des anticorps anti-coronavirus et leurs utilisations
MX2023012643A (es) 2021-04-27 2024-01-05 Generation Bio Co Vectores de adn no virales que expresan anticuerpos terapéuticos y usos de estos.
JP2024519858A (ja) 2021-05-18 2024-05-21 アボット・ラボラトリーズ 小児対象における脳損傷を査定する方法
CA3222291A1 (fr) 2021-06-14 2022-12-22 Jaime MARINO Procedes de diagnostic ou d'aide au diagnostic d'une lesion cerebrale provoquee par de l'energie acoustique, de l'energie electromagnetique, une onde de surpression et/ou le souffle d'une explosio
WO2022271782A1 (fr) * 2021-06-22 2022-12-29 University Of Virginia Patent Foundation Compositions et méthodes de détection et de régulation d'interactions et de signalisation de la fibronectine-intégrine
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
JP2024534849A (ja) 2021-08-31 2024-09-26 アボット・ラボラトリーズ 脳の損傷を診断する方法及びシステム
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
WO2023056268A1 (fr) 2021-09-30 2023-04-06 Abbott Laboratories Méthodes et systèmes de diagnostic de lésion cérébrale
JP2025503439A (ja) 2021-12-17 2025-02-04 アボット・ラボラトリーズ 血液試料におけるｕｃｈ－ｌ１、ｇｆａｐ及び他のバイオマーカーを決定するためのシステム及び方法
CN119256227A (zh) 2022-02-04 2025-01-03 雅培实验室 用于检测样品中泛素羧基末端水解酶l1和/或胶质纤维酸性蛋白的存在或测量其量的侧向流方法、测定和装置
KR20240161965A (ko) 2022-03-14 2024-11-13 제너레이션 바이오 컴퍼니 이종 프라임 부스트 백신 조성물 및 사용 방법
EP4547714A1 (fr) * 2022-06-28 2025-05-07 Adafre BioSciences, LLC Anticorps anti-tnf-alpha et compositions
CN120167040A (zh) 2022-06-29 2025-06-17 雅培实验室 用于确定生物样本中的gfap的磁性定点照护型系统和测定
CN116903738A (zh) * 2022-08-02 2023-10-20 北京绿竹生物技术股份有限公司 一种低甘露糖型抗人肿瘤坏死因子-α单抗及其用途
EP4583855A1 (fr) 2022-09-07 2025-07-16 MDX Management LLC Inhibiteurs de shp-1 pour le traitement du cancer
WO2024059708A1 (fr) 2022-09-15 2024-03-21 Abbott Laboratories Biomarqueurs et méthodes de différenciation entre une lésion cérébrale traumatique légère et très légère
WO2024097804A1 (fr) 2022-11-02 2024-05-10 Mdx Management Llc Combinaison d'un inhibiteur de tyrosine kinase et d'un agent pro-inflammatoire pour le traitement du cancer
AU2024239074A1 (en) 2023-03-17 2025-10-02 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies
WO2024211475A1 (fr) 2023-04-04 2024-10-10 Abbott Laboratories Utilisation de biomarqueurs pour détermination ou suspicion d'une lésion cérébrale acquise subaiguë chez un sujet
WO2024226971A1 (fr) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Dosages, cartouches et kits améliorés pour la détection de biomarqueurs, y compris des biomarqueurs de lésion cérébrale
WO2025038745A1 (fr) 2023-08-16 2025-02-20 Mdx Management Llc Compositions et procédés pour activation de cellules immunitaires
WO2025188921A1 (fr) 2024-03-06 2025-09-12 Mdx Management Llc Inhibiteurs de shp-1 et activateurs de lymphocytes t
WO2025238106A1 (fr) 2024-05-15 2025-11-20 M6P Therapeutics (Switzerland) GmbH Conception de fusion pour dégradation ciblant le lysosome

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680276A (en) * 1977-05-25 1987-07-14 Institut National De La Sante Et De La Recherche Medicale Metal polypeptides
JPS58501544A (ja) 1981-09-08 1983-09-16 ザ　ロツクフエラ−　ユニヴア−シテイ エンドトキシン誘発メディエ−タ−（ショック検定）によるリポプロティンリパ−ゼの抑圧
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL73883A (en) 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4661016A (en) * 1985-04-11 1987-04-28 Mobil Oil Corporation Subsea flowline connector
EP0212489B1 (fr) 1985-08-16 1994-11-30 The Rockefeller University Modulateur de l'activité anabolique et ses applications
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
AU626572B2 (en) 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4940723A (en) * 1988-10-20 1990-07-10 University Of North Carolina, Chapel Hill Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat arthritis
EP0366043B1 (fr) 1988-10-24 1994-03-30 Otsuka Pharmaceutical Co., Ltd. Anticorps monoclonal
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) * 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
EP0486526B2 (fr) 1989-08-07 2001-03-07 Peptech Limited Ligands de liaison du facteur de necrose de tumeurs
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB2279077B (en) 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en) 1991-03-18 2006-11-02 Knight David M Anti-TNF antibodies and peptides of human tumor necrosis factor
US20070298040A1 (en) 1991-03-18 2007-12-27 Centocor, Inc. Methods of treating seronegative arthropathy with anti-TNF antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE69233701T2 (de) * 1991-03-18 2008-04-10 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5328985A (en) 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
EP0605522B1 (fr) * 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5741488A (en) * 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
DE69432412T2 (de) 1993-05-12 2004-01-29 Xoma Corp Gelonin und einen antikörper entahltende immuntoxine
WO1994029347A1 (fr) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Utilisation de fragments d'anticorps en therapie
EP0724651B1 (fr) 1993-10-19 2008-08-20 The Scripps Research Institute Anticorps monoclonaux humains synthetiques diriges contre et neutralisant le virus de l'immunodeficience
EP0659766A1 (fr) 1993-11-23 1995-06-28 Schering-Plough Anticorps monoclonaux humains contre des cytokines humains et méthode de fabrication de tels anticorps
JPH09509835A (ja) 1994-03-04 1997-10-07 メルク エンド カンパニー インコーポレーテッド アラニン走査型突然変異誘発によるｉｎ ｖｉｔｒｏ抗体アフィニティー成熟
JPH07289288A (ja) * 1994-04-27 1995-11-07 L T T Kenkyusho:Kk 抗リウマチ薬の効果評価方法
CA2192821A1 (fr) 1994-06-24 1996-01-04 Wayne R. Gombotz Compositions a base de polypeptides et a liberation lente, et procedes de traitement des affections intestinales inflammatoires
US5561053A (en) 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
GB9416721D0 (en) * 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
WO2000058362A1 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Nouvelles proteines capables de liaison avec la neutrokine alpha et procedes bases sur lesdites proteines
US20060018907A1 (en) 2000-08-07 2006-01-26 Centocor, Inc. Anti-TNF antibodies and peptides of human tumor necrosis factor
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20030012786A1 (en) 2001-05-25 2003-01-16 Teoh Leah S. Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
US20030161828A1 (en) 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20090280065A1 (en) 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
MY151032A (en) 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040054414A1 (en) * 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2006041970A2 (fr) 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Infection a virus respiratoire syncytial (rsv)
KR20150055116A (ko) * 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
NZ567286A (en) 2005-11-01 2012-03-30 Abbott Biotechnolgy Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
WO2007120656A2 (fr) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la polyarthrite rhumatoïde
WO2007120626A2 (fr) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
EP2666472A3 (fr) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite psoriasique
US20090317399A1 (en) 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
JP5535623B2 (ja) 2006-06-30 2014-07-02 アッヴィ バイオテクノロジー リミテッド 自動注射装置
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
EP2684895A1 (fr) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Anticorps anti-hTNfalpha cristallins
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
EP2165194A4 (fr) 2007-05-31 2010-09-08 Abbott Lab BIOMARQUEURS PRÉDICTIFS DE LA RÉACTIVITÉ AUX INHIBITEURS TNF-alpha DANS DES TROUBLES AUTO-IMMUNS
WO2008150490A2 (fr) 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Compositions et utilisations pour le traitement du psoriasis et de la maladie de crohn
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
CA2693771A1 (fr) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Compositions et methodes d'administration pulmonaire d'un inhibiteur du tnf.alpha.
WO2009020654A1 (fr) 2007-08-08 2009-02-12 Abbott Laboratories Compositions et procédés permettant la cristallisation d'anticorps
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
CA2710333A1 (fr) 2008-01-03 2009-07-09 Abbott Biotechnology Ltd. Prediction de l'efficacite a long terme d'un compose dans le traitement du psoriasis
WO2009091912A2 (fr) 2008-01-15 2009-07-23 Abbott Laboratories Vecteurs d'expression de mammifère améliorés et leurs utilisations
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
JP2011511777A (ja) 2008-01-30 2011-04-14 アボット・ラボラトリーズ 抗体断片を結晶化するための組成物及び方法
EP2271671A2 (fr) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Compositions et méthodes de traitement de la perte osseuse
JP5677411B2 (ja) 2009-04-29 2015-02-25 アッヴィ バイオテクノロジー リミテッド 自動注入機器
WO2010129469A1 (fr) 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Formulations stables à concentration protéique élevée d'anticorps anti-tnf-alpha humain
US20120014956A1 (en) 2010-02-02 2012-01-19 Hartmut Kupper Methods and compositions for predicting responsiveness to treatment with tnf-alpha inhibitor
RS57543B1 (sr) 2010-06-03 2018-10-31 Abbvie Biotechnology Ltd Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same

Also Published As

Publication number Publication date
UA57726C2 (uk) 2003-07-15
US20070249813A1 (en) 2007-10-25
RU2012102323A (ru) 2013-07-27
CN1504752A (zh) 2004-06-16
NO20026202L (no) 1998-10-07
US8206714B2 (en) 2012-06-26
US8753633B2 (en) 2014-06-17
WO1997029131A1 (fr) 1997-08-14
BG66509B1 (bg) 2015-11-30
SK106298A3 (en) 1999-03-12
AU2122997A (en) 1997-08-28
RU2458704C2 (ru) 2012-08-20
US20130330357A1 (en) 2013-12-12
CA2243459C (fr) 2002-09-17
HK1214607A1 (en) 2016-07-29
CZ247698A3 (cs) 1998-11-11
SI9720020B (en) 2001-12-31
CA2243459A1 (fr) 1997-08-14
BRPI9707379B8 (pt) 2015-07-07
BG66195B1 (bg) 2012-01-31
JP5422501B2 (ja) 2014-02-19
MX9806347A (es) 1998-10-31
IL206994A0 (en) 2010-12-30
NO983627D0 (no) 1998-08-07
NO983627L (no) 1998-10-07
JP2003177130A (ja) 2003-06-27
CZ292465B6 (cs) 2003-09-17
KR19990082430A (ko) 1999-11-25
ES2198552T3 (es) 2004-02-01
HU0204115D0 (en) 2003-02-28
US20100040604A1 (en) 2010-02-18
CN103275221A (zh) 2013-09-04
NO320657B1 (no) 2006-01-09
BR9707379A (pt) 1999-04-13
JP2013091666A (ja) 2013-05-16
HK1214610A1 (en) 2016-07-29
EP0929578B1 (fr) 2003-05-02
NO20026202D0 (no) 2002-12-23
NZ576716A (en) 2011-02-25
NL300143I1 (nl) 2004-05-03
RU2458704C9 (ru) 2012-12-10
KR100317188B1 (ko) 2002-02-19
US20030092059A1 (en) 2003-05-15
JP5689902B2 (ja) 2015-03-25
HU230048B1 (hu) 2015-06-29
IL151641A0 (en) 2003-04-10
HK1019452A1 (en) 2000-02-11
DK0929578T3 (da) 2003-08-25
NO319955B1 (no) 2005-10-03
UA82823C2 (en) 2008-05-26
MX336813B (es) 2016-02-02
JP4404181B2 (ja) 2010-01-27
NL300143I2 (nl) 2004-07-01
EP0929578A1 (fr) 1999-07-21
RO119831B1 (ro) 2005-04-29
DE122004000003I2 (de) 2007-03-29
US6258562B1 (en) 2001-07-10
HUP9901874A3 (en) 2000-05-29
DE122004000003I1 (de) 2004-09-23
NO2004002I2 (no) 2008-02-04
JP2000507810A (ja) 2000-06-27
US7541031B2 (en) 2009-06-02
CY2463B1 (en) 2005-06-03
HU230515B1 (hu) 2016-10-28
BR9707379B1 (pt) 2009-08-11
RO123028B1 (ro) 2010-07-30
BR9715219B1 (pt) 2010-02-23
JP2010209119A (ja) 2010-09-24
HUP1500179A2 (en) 1999-09-28
US20130330356A1 (en) 2013-12-12
BRPI9715219B8 (pt) 2015-07-07
BG109311A (en) 2006-03-31
NO2017038I1 (no) 2017-08-01
HUP9901874A2 (hu) 1999-09-28
HK1125951A1 (en) 2009-08-21
BG107537A (bg) 2003-09-30
JP5951056B2 (ja) 2016-07-13
DE69721548T2 (de) 2004-04-01
NO2017038I2 (no) 2017-11-17
CN102070715A (zh) 2011-05-25
IL125697A (en) 2005-03-20
NZ512006A (en) 2005-05-27
JP2007045828A (ja) 2007-02-22
TR199801532T2 (xx) 1998-11-23
IL218518A0 (en) 2012-04-30
BG102755A (en) 1999-05-31
BRPI9707379C8 (pt) 2017-12-12
PL193499B1 (pl) 2007-02-28
RU2270030C2 (ru) 2006-02-20
BG64564B1 (bg) 2005-07-29
NO20040154L (no) 1998-10-07
JP3861118B2 (ja) 2006-12-20
CY2005011I1 (el) 2011-06-08
JP5759526B2 (ja) 2015-08-05
DE69721548D1 (de) 2003-06-05
NO322755B1 (no) 2006-12-04
SK284040B6 (sk) 2004-08-03
PT929578E (pt) 2003-09-30
HK1214608A1 (en) 2016-07-29
JP4890997B2 (ja) 2012-03-07
US7223394B2 (en) 2007-05-29
HK1214609A1 (en) 2016-07-29
HK1066860A1 (en) 2005-04-01
JP2016104798A (ja) 2016-06-09
HK1125972A1 (en) 2009-08-21
CN101712720A (zh) 2010-05-26
DE122004000004I1 (de) 2004-08-12
NO20040052L (no) 1998-10-07
HU221984B1 (hu) 2003-03-28
CN103275221B (zh) 2016-08-17
BG112042A (bg) 2015-10-30
AU722077B2 (en) 2000-07-20
SI9720020A (sl) 1999-10-31
RU2005113954A (ru) 2006-11-20
PL328411A1 (en) 1999-01-18
PL188192B1 (pl) 2004-12-31
RU2003120859A (ru) 2005-01-10
CN100429232C (zh) 2008-10-29
BG64776B1 (bg) 2006-03-31
NO316711B1 (no) 2004-04-13
NZ331579A (en) 2001-06-29
BG110703A (en) 2010-10-29
US20120258114A1 (en) 2012-10-11
JP2014055150A (ja) 2014-03-27
CN1215407A (zh) 1999-04-28
NZ562935A (en) 2009-06-26
US20090155205A1 (en) 2009-06-18
CN1300173C (zh) 2007-02-14
HU228630B1 (en) 2013-04-29
NZ536216A (en) 2006-08-31
JP2015108011A (ja) 2015-06-11
ATE239041T1 (de) 2003-05-15
US20130115224A1 (en) 2013-05-09
US8372400B2 (en) 2013-02-12
IL125697A0 (en) 1999-04-11

Similar Documents

Publication Publication Date Title
LU91062I2 (fr) Adalimumab et ses dérivés pharmaceutiquement acceptables-trudexa
CA2389943A1 (fr) Anticorps humains se fixant au facteur necrosant des tumeurs de type .alpha.
LU92159I2 (fr) Ustekinumab et ses dérivés pharmaceutiquement acceptables (STELARA®)
DE60315815D1 (de) ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON
MX343996B (es) Anticuerpos humanos que ligan el tnfa humano.